AD-VISE: Better Patient Outcomes Tied to Achieving MDA at 6 Months with Upadacitinib

Key Takeaways

• Achieving minimal disease activity (MDA) with upadacitinib was associated with higher rates of optimal patient-reported outcomes at 6 months, according to new research presented at AAD 2026. 
• DLQI 0/1 and ADCT 0/1 were achieved by 72.3% and 64.5% of MDA patients, respectively vs lower rates in moderate or non-responders.
• Investigators said the real-world findings from AD-VISE align with prior clinical trials.

Patients with atopic dermatitis (AD) treated with upadacitinib who achieved minimal disease activity (MDA) demonstrated markedly improved patient-reported outcomes (PROs) compared with those meeting moderate or no treatment targets, according to findings from the real-world AD-VISE study presented at the 2026 American Academy of Dermatology Annual Meeting.

In this ongoing, prospective, multi-country observational study, adults and adolescents with AD were stratified after 6 months of treatment by Eczema Area and Severity Index (EASI) and Worst Pruritus Numerical Rating Scale (WP-NRS) thresholds. MDA was defined as EASI ≤3 and WP-NRS 0/1, with comparator groups defined by less stringent response criteria.

According to the data, 72.3% of patients achieved MDA reached DLQI 0/1 vs 21.7% and 9.9% in the moderate and neither target groups, respectively.  ADCT 0/1 was achieved by 64.5% of MDA patients vs 7.3% and 1.8% in the comparator groups. Patients achieving MDA were 3.3 to 8.8 times more likely to reach optimal composite PRO scores than those meeting moderate targets, and up to 35.8 times more likely than those meeting neither target.

Additional PRO measures (sleep interference, patient satisfaction (PGIT 6/7), and flare reduction) also favored MDA, with higher proportions of patients reporting no flares and improved sleep. Limitations include the observational design and absence of safety data in this analysis.

“In the AD-VISE study, patients who achieved minimal disease activity after 6 months of treatment were more likely to report minimal to no impact of AD on quality of life compared to patients who achieved moderate or neither treatment targets,” the authors said in the study abstract. “These results provide a rationale for aiming to achieve Minimal Disease Activity in clinical practice.”

Source: Beecker J, Pereyra-Rodriquez JJ, Luna P, Cecchin M, Reich A, Stratigos A, Prefontaine D, Ta R, Lane M, Armendariz Y, Gooderham M. Achievement of Minimal Disease Activity and Moderate Treatment Targets and Patient Reported Outcomes in the Real-World AD-VISE Study. Abstract 74626. Presented at: American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver.